Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Employees

1,310

Sector

Biotechnology & Medical Research

Calendar

18/09/2024 - Bank of America Global Healthcare Conference - Fireside Chat

More about the company

Quotes

Date	Price	Change	Volume
09/09/24	25.51 $	+1.43%	1,533,169
06/09/24	25.15 $	-1.64%	1,355,060
05/09/24	25.57 $	-0.16%	1,167,973
04/09/24	25.61 $	-0.85%	1,659,983

Delayed Quote Nasdaq, September 09, 2024 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.51USD

Average target price

27.52USD

Spread / Average Target

+7.89%

Consensus

Profit revisions

Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 09/09/2024 BST			5-day change	1st Jan Change
25.51 ^USD	+1.43%		-2.00%	+6.34%

09-06	Transcript : Exelixis, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-06-2024 10:15 AM
09-04	Transcript : Exelixis, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 09:15 AM

Capitalization	7.28B 555B	P/E ratio 2024 *	16.4x	P/E ratio 2025 *	17x
Enterprise value	6.24B 476B	EV / Sales 2024 *	3.04x	EV / Sales 2025 *	2.88x
Free-Float	97.77%	Yield 2024 *	-	Yield 2025 *	-

Transcript : Exelixis, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-06-2024 10:15 AM	09-06
Transcript : Exelixis, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 09:15 AM	09-04
Exelixis Insider Sold Shares Worth $3,398,750, According to a Recent SEC Filing	08-12	MT
Exelixis Insider Sold Shares Worth $2,375,000, According to a Recent SEC Filing	08-12	MT
Exelixis Insider Sold Shares Worth $2,077,600, According to a Recent SEC Filing	08-12	MT
Exelixis Insider Sold Shares Worth $3,398,750, According to a Recent SEC Filing	08-12	MT
Truist Securities Lifts Exelixis' Price Target to $33 From $32, Keeps Buy Rating	08-07	MT
Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors	08-07	CI
Exelixis Shares Rise After Higher Q2 Results	08-07	MT
Market meltdown averted	08-07
Exelixis Q2 Non-GAAP Earnings, Revenue Rise; 2024 Revenue Guidance Updated -- Shares Up After Hours	08-06	MT
Transcript : Exelixis, Inc., Q2 2024 Earnings Call, Aug 06, 2024	08-06
Exelixis Guides For 2024 Revenue of $1.975-$2.075 Billion, vs CIQ Analyst Consensus of $1.88 Billion	08-06	MT

Truist Securities Lifts Exelixis' Price Target to $33 From $32, Keeps Buy Rating	08-07	MT
Analyst recommendations: Citigroup, Constellation Brands, Broadcom, JPMorgan, Bunzl...	07-04
Exelixis Insider Bought Shares Worth $8,733,955, According to a Recent SEC Filing	05-31	MT
Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target	05-14	MT
RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept	05-01	MT

Exelixis, Inc. Share Price

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Valuation: Exelixis, Inc.

Chart: Exelixis, Inc.

Latest news: Exelixis, Inc.

Last Transcript: Exelixis, Inc.

Analysts' recommendations: Exelixis, Inc.

Press Releases: Exelixis, Inc.

News in other languages: Exelixis, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Exelixis, Inc.

ETFs: Exelixis, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly earnings, Rate of surprise

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September	08-28	BU
Colorectal Cancer Pipeline Drugs 2024 \| Exelixis, Mirati Therapeutics, Merck Sharp & Dohme LLC, Daiichi Sankyo Company, Inspirna, Lyell Immunopharma, Genentech, Cantargia AB, Arcus Biosciences Inc.	08-21	AQ
Exelixis Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors	08-07	AQ
Exelixis: Q2 Earnings Snapshot	08-06	AQ
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update	08-06	BU

RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU.: Amgen, Fortinet, Moderna, Airbnb, BP...	08-07
RECOMENDACIONES DE LOS ANALISTAS UK/EE.UU: Citigroup, Constellation Brands, Broadcom, JPMorgan, Bunzl...	07-04
Ipsen : extension de la collaboration avec Exelixis	07-02
Ipsen étend l'accord de licence du Cabometyx à de nouveaux traitements	07-02
Ipsen s'apprête à présenter de nouvelles données positives sur le Cabometyx	01-23

1 day	+1.43%
1 week	-2.00%
Current month	-2.00%
1 month	-5.41%
3 months	+16.59%
6 months	+14.86%
Current year	+6.34%

Director	Title	Age	Since
Michael Morrissey CEO	Chief Executive Officer	63	31/01/00
Christopher Senner DFI	Director of Finance/CFO	56	14/07/15
Amy Peterson CTO	Chief Tech/Sci/R&D Officer	57	22/08/23

Manager	Title	Age	Since
Jack Wyszomierski BRD	Director/Board Member	68	31/01/04
George Poste BRD	Director/Board Member	79	31/07/04
Stelios Papadopoulos FOU	Founder	75	14/11/94

Name	Weight	AuM	1st Jan change	Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	13.24%	228 M€	+23.24%	-
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	2.62%	1 M€	+11.31%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.67%	7 M€	0.00%
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	1.59%	2 M€	+16.70%
IQ U.S. MID CAP R&D LEADERS ETF - USD	1.30%	4 M€	+20.15%

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
EXELIXIS, INC.	+1.43%	-2.00%	+15.38%	+30.55%	7.28B
REGENERON PHARMACEUTICALS, INC.	+1.17%	-3.37%	+37.81%	+77.18%	124B
VERTEX PHARMACEUTICALS INCORPORATED	+0.66%	-5.00%	+37.33%	+150.47%	122B
ARGENX SE	-0.44%	+6.19%	+0.87%	+77.78%	32.94B
BIONTECH SE	+11.77%	+13.95%	-16.32%	-71.39%	23.9B
BEIGENE, LTD.	+1.04%	+0.80%	+0.35%	-42.70%	20.54B
GENMAB A/S	+0.75%	-0.83%	-28.45%	-33.36%	17.42B
WUXI APPTEC CO., LTD.	+1.57%	+4.43%	-48.28%	-72.01%	15.77B
VAXCYTE, INC.	+3.32%	+42.74%	+127.47%	+343.56%	14.26B
SAREPTA THERAPEUTICS, INC.	-0.95%	-5.96%	+6.49%	+58.60%	12.18B
Average	+2.01%	+5.03%	+13.26%	+51.87%	38.94B
Weighted average by Cap.	+1.52%	+0.30%	+24.67%	+81.99%

	2024 *	2025 *
Net sales	2.05B 157B	2.07B 158B
Net income	467M 35.62B	447M 34.1B
Net Debt	-1.03B -78.98B	-1.31B -100B